A Phase I/II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Mogamulizumab (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 30 May 2018 Planned initiation date changed from 9 May 2018 to 29 Jun 2018.
- 28 Feb 2018 Planned initiation date changed from 9 Feb 2018 to 9 May 2018.
- 18 Oct 2017 New trial record